Daclizumab Biosimilar - Research Grade,ichor.bio,ICH5021
Detects human CD25. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Daclizumab.
Host
CHO cells
Reactivity
Human
Platform ID
BAB510276772
ichor.bio
Contact
Tel:
Fax:
Email:
Product Specifications
Scientific Background
Synonyms
Specifications
NameDaclizumab Biosimilar - Research Grade
Cat. No.ICH5021
Accession NumberP01589
HostCHO cells
IsotypeHuman IgG1
ReactivityHuman
Concentration5mg/ml
TargetIL2RA
Purity>95% by SDS-PAGE
Endotoxin Level≤ 1.0 EU/mg as determined by the LAL method
ShippingBlue ice
FormulationICH3002
StorageThis biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.
Regulatory StatusFor research use only
Scientific Background
RUO daclizumab biosimilar is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis. Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.
Synonyms
Alpha subunit IL-2R, interleukin 2 receptor, CD25
Category Paths
- Products>Primary Antibodies>Biosimilar Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.